Unknown PHASE1 INTERVENTIONAL 2-arm NCT04814589

Bioequivalence of Ezetimibe Tablets in Healthy Subjects

Bioequivalence of Ezetimibe Tablets in Healthy Subjects: A Single-dose and Two-period Crossover Study

Sponsor: Cao Yu

Interventions ezetimibe tablets ezetimibe tablets(Ezetrol ®)

Updated 4 times since 2021 Last updated: Mar 22, 2021 Started: Mar 13, 2021 Primary completion: Jun 30, 2021 Completion: Jul 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Therapeutic Equivalency and is currently ongoing. Cao Yu leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Apr 2023 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Apr 2021 — Apr 2023 [monthly]

Recruiting PHASE1

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cao Yu

Data source: The Affiliated Hospital of Qingdao University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Qingdao, China